Page 856 - Cote clinical veterinary advisor dogs and cats 4th
P. 856

Heart Failure, Chronic  412.e1


           ADDITIONAL SUGGESTED                RELATED CLIENT EDUCATION
           READINGS                            SHEETS
  VetBooks.ir  Boswood  A,  et  al:  Effect  of  pimobendan  in  dogs   Consent to Perform Echocardiography           Diseases and   Disorders
            with preclinical myxomatous mitral valve disease
                                               Dilated Cardiomyopathy
            and cardiomegaly: the EPIC study—a randomized
            clinical trial. J Vet Intern Med 30(6):1765-1779,
            2016.                              Heart Failure
                                               How to Count Respirations and Monitor
           Chetboul V, et al: Comparative adverse cardiac effects   Respiratory Effort
            of pimobendan and benazepril monotherapy in   Mitral/Tricuspid Regurgitation Due to Myxo-
            dogs with mild degenerative mitral valve disease:   matous Heart Valve Disease
            a prospective, controlled, blinded, and randomized
            study. J Vet Intern Med 21(4):742-753, 2007.
           Chetboul V, et al: Effect of benazepril on survival and
            cardiac events in dogs with asymptomatic mitral
            valve disease: a retrospective study of 141 cases. J
            Vet Intern Med 22:905-914, 2008.
           Ettinger  SJ,  et al:  Effects  of  enalapril  maleate  on
            survival of dogs with naturally acquired heart
            failure. The Long-Term Investigation of Veterinary
            Enalapril (LIVE) study group. J Am Vet Med Assoc
            213(11):1573-1577, 1998.
           Häggström J, et al: Effect of pimobendan or bena-
            zepril  hydrochloride  on survival times  in  dogs
            with congestive heart failure caused by naturally
            occurring myxomatous mitral valve disease: the
            QUEST study. J Vet Intern Med 22:1124-1135,
            2008.
           Häggström  J,  et  al:  An  update  on  treatment  and
            prognostic indicators in canine myxomatous
            mitral valve disease. J Small Anim Pract 50(suppl
            1):25-33, 2009.
           Jeunesse E, et al: Effect of spironolactone on diuresis
            and urine sodium and potassium excretion in
            healthy dogs. J Vet Cardiol 9(2):63-68, 2007.
           Keene BW, et al: Management of heart failure in
            dogs. In Bonagura JD, et al, editors: Kirk’s Current
            veterinary therapy XIV, St. Louis, 2009, Saunders,
            pp 769-780.
           Luis Fuentes V: Management of feline myocardial
            disease.  In  Bonagura  JD,  et  al,  editors:  Kirk’s
            Current veterinary therapy XIV, St. Louis, 2009,
            Saunders, pp 809-815.
           MacDonald KA, et al: Effect of spironolactone on
            diastolic function and left ventricular mass in Maine
            coon cats with familial hypertrophic cardiomyopa-
            thy. J Vet Intern Med 22(2):335-341, 2008.
           Ouellet M, et al: Effect of pimobendan on echocar-
            diographic values in dogs with asymptomatic mitral
            valve  disease.  J  Vet  Intern  Med  23(2):258-263,
            2009.
           Sisson D, et al: Management of heart failure:
            principles of treatment, therapeutic strategies, and
            pharmacology. In Fox PR, et al, editors: Textbook
            of canine and feline cardiology, ed 2, Philadelphia,
            1999, Saunders, pp 216-250.
           The BENCH (BENazepril in Canine Heart disease)
            Study Group: Long-term tolerability of benazepril
            in dogs with congestive heart failure. J Vet Cardiol
            6(1):7-13, 2004.


















                                                      www.ExpertConsult.com
   851   852   853   854   855   856   857   858   859   860   861